SER (Serina Therapeutics) Ending Cash Position: $24.53 Mil (As of Mar. 2026)


SER Serina Therapeutics Inc SER
12 GF Score
Price $2.10
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Ending Cash Position?

Serina Therapeutics SER -1.87% 12 Ending Cash Position is $24.53 Mil as of Mar. 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Serina Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $24.53 Mil.

Serina Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($8.62 Mil) to Dec. 2025 ($3.06 Mil) but then increased from Dec. 2025 ($3.06 Mil) to Mar. 2026 ($24.53 Mil).

Serina Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($7.62 Mil) to Dec. 2024 ($3.67 Mil) and declined from Dec. 2024 ($3.67 Mil) to Dec. 2025 ($3.06 Mil).

Serina Therapeutics Ending Cash Position Related Terms

Serina Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Ending Cash Position Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
0.32 0.53 7.62 3.67 3.06

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.27 6.04 8.62 3.06 24.53
SER
12GF Score
Serina Therapeutics Inc SER
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Serina Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.672+-0.616
=3.06

Serina Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.056+21.47
=24.53

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $24.53 Mil mean?
Serina Therapeutics (SER) has a Ending Cash Position of $24.53 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Serina Therapeutics and its competitors.
Is Serina Therapeutics' Ending Cash Position too high?
Serina Therapeutics' current Ending Cash Position is $24.53 Mil. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Ending Cash Position compare to NRSN and IGC?
Serina Therapeutics' Ending Cash Position of $24.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current Ending Cash Position is $24.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current Ending Cash Position of $24.53 Mil. The current Ending Cash Position is $24.53 Mil. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Serina Therapeutics (SER), the current Ending Cash Position is $24.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price